BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 31190812)

  • 21. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR.
    Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK
    Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
    Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
    ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.
    Xu PY; Kankala RK; Pan YJ; Yuan H; Wang SB; Chen AZ
    Int J Nanomedicine; 2018; 13():4685-4698. PubMed ID: 30154654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
    Chen Y; Bathula SR; Li J; Huang L
    J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
    Wei X; Song M; Li W; Huang J; Yang G; Wang Y
    Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
    Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
    ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
    Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
    Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
    Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
    ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
    Huang R; Yao X; Chen Y; Sun X; Lin Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
    Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
    Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
    Li Z; Zhang L; Tang C; Yin C
    Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
    Tiash S; Chowdhury EH
    J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA.
    Kang Y; Lu L; Lan J; Ding Y; Yang J; Zhang Y; Zhao Y; Zhang T; Ho RJY
    Acta Biomater; 2018 Mar; 68():137-153. PubMed ID: 29288085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors.
    Liu J; Song L; Liu S; Zhao S; Jiang Q; Ding B
    Angew Chem Int Ed Engl; 2018 Nov; 57(47):15486-15490. PubMed ID: 30288887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
    Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
    Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
    Wei G; Yang G; Wei B; Wang Y; Zhou S
    Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
    Chen W; Yuan Y; Cheng D; Chen J; Wang L; Shuai X
    Small; 2014 Jul; 10(13):2678-87. PubMed ID: 24668891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.